Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis

Journal of Neuroimmunology

Volumn 201-202, Issue C, 2008, Pages 95-103

  Zisimopoulou, Paraskevi ^a   Lagoumintzis, George ^b   Kostelidou, Kalliopi ^a   Bitzopoulou, Kalliopi ^a,b   Kordas, Gregory ^b   Trakas, Nikolaos ^a   Poulas, Konstantinos ^b   Tzartos, Socrates J ^a,b  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Acetylcholine receptor autoantibodies; Extracellular domains; Immunoadsorption; Myasthenia gravis; Plasmapheresis; Therapy

Indexed keywords

AUTOANTIBODY; NICOTINIC RECEPTOR;

APHERESIS; HUMAN; IMMUNOADSORPTION; IN VITRO STUDY; IN VIVO STUDY; LEWIS RAT; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIGENS; AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; PLASMAPHERESIS; PROTEIN SUBUNITS; RECEPTORS, CHOLINERGIC;

EID: 51749101713     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.06.020     Document Type: Review

References (51)

1. Agius M.A., Richman D.P., and Vincent A. Specific antibodies in the diagnosis and management of autoimmune disorders of neuromuscular transmission and related diseases. In: Kaminsky H.J. (Ed). Current Clinical Neurology: Myasthenia Gravis and Related Disorders (2003) 177-196
2. Berg D., Shoop R., Chang K., et al. Nicotinic acetylcholine receptors in ganglionic transmission. Experimental Pharmacology vol. 144 (2000), Springer, New York 247-270
3. Bitzopoulou, K., Kostelidou, K., Poulas, K., Tzartos, S.J., submitted for publication. Mutant forms of the extracellular domain of the human acetylcholine receptor-subunit with improved solubility and enhanced antigenicity. The importance of the Cys-loop. BBA.
4. Brannagan III T.H., Nagle K.J., Lange D.J., and Rowland L.P. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47 (1996) 674-677
5. Brejc K., van Dijk W.J., Klaassen R.V., Schuurmans M., van Der Oost J., Smit A.B., and Sixma T.K. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411 (2001) 269-276
6. Chiu H.C., Chen W.H., and Yeh J.H. The six year experience of plasmapheresis in patients with myasthenia gravis. Therap. Apher. 4 (2000) 291-295
7. Conti-Fine B.M., and Kaminski H.J. Autoimmune neuromuscular transmission disorders: myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum 7 (2001)
8. Dalakas M.C. Immunotherapies in the treatment of neuromuscular disorders. Neuromuscular Disorders in Clinical Practice (2002), Butterworth Heinemann, Boston 364-383
9. Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., and Spitler L.E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N. Engl. J. Med. 297 (1977) 1134-1140
10. Engel A.G., Lambert E.H., Mulder D.M., Torres C.F., Sahashi K., Ber, torini T.E., and Whitaker J.N. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann. Neurol. 11 (1982) 553-569
11. Ferrero B., Durelli L., Cavallo R., Dutto A., Aimo G., Pecchio F., and Bergamasco B. Therapies for exacerbation of myasthenia gravis. The mechanism of action of intravenous high-dose immunoglobulin G. Ann. N. Y. Acad. Sci. 681 (1993) 563-566
12. Fostieri E., Kostelidou K., Poulas K., and Tzartos S.J. Recent advances in the understanding and therapy of myasthenia gravis. Future Neurol. 1 (2006) 799-801
13. Gajdos P., Outin H.D., Morel E., Raphael J.C., and Goulon M. High-dose intravenous gamma globulin for myasthenia gravis: an alternative to plasma exchange. Ann. N.Y. Acad. Sci. 505 (1987) 842-844
14. Grando S., and Horton R. The keratinocyte cholinergic system with acetylcholine as an epidermal cytotransmitter. Curr. Opin. Dermatol. 4 (1997) 262-268
15. Guo C.Y., Li Z.Y., Xu M.Q., and Yuan J.M. Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum. J. Immunol. Methods 303 (2005) 142-147
16. Kaiser S., Soliokov L., and Wonnacott S. Presynaptic neuronal nicotinic receptors: pharmacology, heterogeneity and cellular mechanisms. Experimental Pharmacology vol. 144 (2000), Springer, New York 193-212
17. Kaminski H.J. Myasthenia gravis. Neuromuscular Disorders in Clinical Practice (2001), Butterworth Heinemann, MA 916-930
18. Kaminski H.J. Treatment of myasthenia gravis. Current Clinical Neurology: Myasthenia Gravis and Related Disorders (2003) 197-221
19. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat. Rev. Neurosci. 3 (2002) 102-114
20. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345 (2001) 747-755
21. Kostelidou K., Trakas N., Zouridakis M., Bitzopoulou K., Sotiriadis A., Gavra I., and Tzartos S.J. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor. FEBS J. 273 (2006) 3557-3568
22. Kostelidou K., Trakas N., and Tzartos S.J. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency. J. Neuroimmunol. (2007)
23. Lang B., Newsom-Davis J., Prior C., and Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J. Physiol. 344 (1983) 335-345
24. Lindstrom J. The structures of neuronal nicotinic receptors. Experimental Pharmacology vol. 144 (2000), Springer, New York 101-162
25. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
26. Lindstrom J., Campbell M., and Nave B. Specificities of antibodies to acetylcholine receptors. Muscle Nerve 1 (1978) 140-145
27. Loutrari H., Tzartos S.J., and Claudio T. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera. Eur. J. Immunol. 22 (1992) 2949-2956
28. Macklin K.D., Maus A.D., Pereira E.F., Albuquerque E.X., and Conti-Fine B.M. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 287 (1998) 435-439
29. Mat ic G., Winkler R.E., Tiess M., and Ramlow W. Selective apheresis-time for a change. Int. J. Artif. Organs 24 (2001) 4-7
30. Maus A.D., Pereira E.F., Karachunski P.I., Horton R.M., Navaneetham D., Macklin K., Cortes W.S., Albuquerque E.X., and Conti-Fine B.M. Human and rodent bronchial epithelial cells express functional nicotinic acetylcholine receptors. Mol. Pharmacol. 54 (1998) 779-788
31. Mossman S., Vincent A., and Newsom-Davis J. Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect. J. Neurol. Sci. 84 (1988) 15-28
32. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
33. Pinching A.J., Peters D.K., Newso, and m-Davis J. Remission of myasthenia gravis following plasma-exchange. Lancet 2 (1976) 1373-1376
34. Psaridi-Linardaki L., Mamalaki A., Remoundos M., and Tzartos S.J. Expression of soluble ligand- and antibody-binding extracellular domain of human muscle acetylcholine receptor alpha subunit in yeast Pichia pastoris. Role of glycosylation in alpha-bungarotoxin binding. J. Biol. Chem. 277 (2002) 26980-26986
35. Psaridi-Linardaki L., Mamalaki A., and Tzartos S.J. Future therapeutic strategies in autoimmune myasthenia gravis. Ann. N. Y. Acad. Sci. 998 (2003) 539-548
36. Psaridi-Linardaki L., Trakas N., Mamalaki A., and Tzartos S.J. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy. J. Neuroimmunol. 159 (2005) 183-191
37. Ptak J. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis. Transfus. Apher. Sci. 30 (2004) 125-129
38. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
39. Sekhon H.S., Jia Y., Raab R., Kuryatov A., Pankow J.F., Whitsett J.A., Lindstrom J., S, and pindel E.R. Prenatal nicotine increases pulmonary alpha7 nicotinic receptor expression and alters fetal lung development in monkeys. J. Clin. Invest. 103 (1999) 637-647
40. Shillito P., Molenaar P.C., Vincent A., Leys K., Zheng W., van den Berg R.J., Plo, mp J.J., van Kempen G.T., Chauplannaz G., Wintzen A.R., et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38 (1995) 714-722
41. Sideris S., Lagoumintzis G., Kordas G., Kostelidou K., Sotiriadis A., Poulas K., and Tzartos S.J. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture. J. Neuroimmunol. 189 (2007) 111-117
42. Skok M., Gr, ailhe R., and Changeux J.P. Nicotinic receptors regulate B lymphocyte activation and immune response. Eur. J. Pharmacol. 517 (2005) 246-251
43. Takamori M., and Maruta T. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Therap. Apher. 5 (2001) 340-350
44. Tzartos S., Hochschwender S., Vasquez P., and Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J. Neuroimmunol. 15 (1987) 185-194
45. Tzartos S.J., Bitzopoulou K., Gavra I., Kordas G., Jacobson L., Kostelidou K., Lagoumintzis G., Lazos O., Poulas K., Sideris S., Sotiriadis A., Trakas N., and Zisimopoulou P. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Myasthenia Gravis and Related Disorders: Ann N Y Acad Sci XIth International Conference vol. 1131 (2008) est. pub date May 2008
46. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. Mol. Biol. 346 (2005) 967-989
47. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., and Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003) 384-388
48. Yamazaki Z., Fujimori Y., Takahama T., Inoue N., Wada T., Kazama M., Morioka M., Abe T., Yamawaki N., and Inagaki K. Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif. Intern. Organs 28 (1982) 318-323
49. Zisimopoulou, P., Lagoumintzis, G., Poulas, K., Tzartos, S., in press. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains. J Neuroimmunol.
50. Zoli M. Distribution of cholinergic neurons in the mammalian brain with special reference to their relationship with neuronal nicotinic receptors. Experimental Pharmacology vol. 144 (2000), Springer, New York 13-30
51. Zouridakis M., Kostelidou K., Sotiriadis A., Stergiou C., Eliopoulos E., Poulas K., and Tzartos S.J. Circular dichroism studies of extracellular domains of human nicotinic acetylcholine receptors provide an insight into their structure. Int. J. Biol. Macromol. 41 (2007) 423-429